People

Nathan Higginson-Scott was appointed chief research and development officer of Gensaic in January 2026 to lead scientific strategy and therapeutic development. He previously served as chief technology officer and senior vice president of drug creation at Seismic Therapeutic and as vice president of biotherapeutics at Pandion Therapeutics. Earlier, he worked at Pfizer. He earned a doctorate in molecular immunology and a master’s degree from Imperial College London and a microbiology degree from the University of Kent.